Login to Your Account

Genzyme Expands Oncology Portfolio, Buys ILEX For $1B

By Aaron Lorenzo

Monday, March 1, 2004
Continuing with a growth-by-acquisition theme, Genzyme Corp. late Thursday unveiled plans for a $1 billion stock purchase of cancer drug developer ILEX Oncology Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription